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Purpose: The aim of the study was to elucidate the genetic background of retinitis pigmentosa (RP) in a Faroe Islands
population, a genetic isolate in the North Atlantic Ocean.
Methods: Blood samples were collected from subjects diagnosed with RP and their families. DNA from affected
individuals underwent single nucleotide polymorphism microarray analysis and homozygosity mapping followed by
sequence analysis of candidate genes.
Results: We identified 25 cases of nonsyndromic RP corresponding to a prevalence of 1 in 1,900. Single nucleotide
polymorphism analysis revealed a homozygous region on chromosome 2q, common to patients in four families, which
harbored the RP gene MER tyrosine kinase protooncogene (MERTK). A deletion of 91 kb was identified in seven patients,
representing 30% of the analyzed Faroese cases of nonsyndromic RP. The clinical course of six patients who were
homozygous for the deletion showed onset in the first decade followed by a rapid deterioration of both rod and cone
photoreceptor function. Early macular involvement was present, in accordance with that of other reported patients with
MERTK mutations.
Conclusions: Previous studies have shown a frequency of less than 1% of MERTK mutations in RP patients. The 91-kb
deletion encompassing exons 1–7 of MERTK is a common founder mutation in the Faroe Islands, responsible for around
30% of RP, and together with mutations in protocadherin 21 (PCDH21) accounts for more than half of the retinal dystrophy
cases.
The Faroe Islands are a self-governing region of Denmark
and consist of 18 small islands situated in the North Atlantic
Ocean, 300 km northwest of Scotland between Iceland and
Norway. The islands were inhabited by Norse Vikings about
1,000  years  ago,  and  over  the  centuries  the  population
remained small and isolated. This isolation combined with a
recent  expansion  in  population  size  to  around  48,000
inhabitants explains a high incidence of certain autosomal-
recessive disorders as a result of founder effects [1-3]. We
identified retinitis pigmentosa (RP; OMIM 268000) as an
additional  disorder  with  a  high  prevalence  in  the  Faroe
Islands.
RP is characterized by progressive visual loss due to
abnormalities of retinal photoreceptors. In the early stages,
rod function is predominantly impaired, leading to defective
dark  adaptation  and  night  blindness.  This  is  followed  by
impairment of visual acuity due to loss of cone cells and
eventually complete blindness.
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The reported prevalence of RP varies from 1 in 4,000 to
1 in 2,500 [4]. Autosomal-recessive inheritance is found in
15%–25% of RP, autosomal-dominant in 5%–20%, X-linked-
recessive in 5%–15%, and simplex (unknown inheritance) in
40%–50%  [5].  A  large  number  of  genes  responsible  for
autosomal-recessive  RP  have  been  identified,  each
responsible for only a small percentage of RP. One of these
genes  is  mer  tyrosine  kinase  protooncogene  (MERTK;
GenBank NM_006343). Shortly after the identification of a
Mertk mutation in a rat—an extensively studied model of
retinal  dystrophy  [6]—at  the  Royal  College  of  Surgeons
(RCS), Gal and coworkers reported the first three mutations
in the human ortholog MERTK [7]. To date 11 pathogenic
sequence variants have been published in seven unrelated
individuals or families [8-14]. Three of the mutations were
detected in consanguineous families originating in the Middle
East [10], Saudi Arabia [13], Spain [11], and Morocco [12].
Screening of DNA samples from individuals with autosomal-
recessive RP (ARRP) showed that MERTK mutations are a
rare cause of retinal dystrophy in humans, affecting less than
1% of the probands [7,9,10,12,13].
METHODS
Human subjects: Probands with RP, where one or both parents
were born in the Faroe Islands, were identified from the files
Molecular Vision 2011; 17:1485-1492 <http://www.molvis.org/molvis/v17/a167>
Received 3 December 2010 | Accepted 1 June 2011 | Published 4 June 2011
© 2011 Molecular Vision
1485at the National Eye Clinic, Hellerup, and the Eye Department,
National  Hospital  of  the  Faroe  Islands,  Tórshavn,  Faroe
Islands.  Clinical  data  were  obtained  retrospectively  from
patient files from 1946 through 2004. Apart from RP, the
patients were healthy and had no other eye disorders. Blood
sampling from probands and family members was performed
in  2007,  according  to  an  agreement  with  the  Genetic
Biobank,  which  also  supplied  genealogical  information.
Peripheral blood samples were collected in EDTA vacutainer
tubes and sent to the Genetic Biobank, where DNA extraction
was performed using the QIAamp DNA Mini Kit (Qiagen,
Dusseldorf, Germany). The study adhered to the tenets of the
Helsinki  Declaration  and  was  approved  by  the  Faroese
Scientific Ethical Committee. Consent was obtained from all
participants after oral and written information was provided.
Microarray analysis and homozygosity mapping: DNA from
19 patients with RP was used for a genome-wide search for
homozygosity with the Affymetrix GeneChip 50K Xba array
(Affymetrix Inc., Santa Clara, CA). In brief, 250 ng of DNA
was digested with the restriction enzyme XbaI, mixed with
Xba adapters, and ligated with the T4 DNA ligase. The ligated
DNA was PCR-amplified in four PCR reactions, pooled, and
purified.  The  purified  PCR  product  was  fragmented  with
DNase  I  and  end-labeled  with  biotin.  The  samples  were
hybridized to an array for 18 h in a hybridization oven. The
array was washed, stained, and scanned with an Affymetrix
GeneChip scanner 3000. Affymetrix software was used to
analyze  the  data  that  was  exported  to  an  Excel  file  and
manually inspected for homozygous regions.
Mutation analysis: PCR was performed using the Promega
(Madison, WI) GoTaq system with the following conditions:
0.2  mM  deoxyribonucleotide  triphosphate  (dNTPs),
1× buffer, 1.5 mM MgCl2, 0.5 mM of each forward and reverse
primer (Table 1), 10 ng template, and 0.5 U polymerase in a
total volume of 50 µl. The PCR program was: 94 °C for 2 min,
35 cycles of denaturing at 94 °C for 30 s, annealing at 60 °C
for 30 s, and extension at 72 °C for 30 s, and a final extension
step of 72 °C for 7 min.
Sequencing  was  performed  with  the  ABI  Big  Dye
Terminator  version  1.1  Cycle  Sequencing  Kit  (Applied
Biosystems, Foster City, CA). The sequencing reactions were
vacuum  purified  with  the  Montage  Seq96  Sequencing
Reaction Cleanup Kit (Millipore SA, SaintQuentin, France)
and analyzed on an ABI 3130xl Gene Analyzer (Applied
Biosystems).
The  data  were  analyzed  with  Sequencing  Analysis
version  5.2  software  (Applied  Biosystems),  and  mutation
screening was performed using Mutation Surveyor version 3.1
software (SoftGenetics, State College, PA).
To screen for the 91-kb deletion, a triple-primer PCR
assay was designed: the forward primer (5′-GTC ATT ATT
GAG CTC AGT GCG-3′) was located immediately upstream
of the deletion junction (5′-AAA TTG AAA ATA ATA TGC
CAG  GC-3′),  whereas  one  reverse  primer  spanned  the
deletion junction, resulting in a deletion-specific PCR product
of 264 bp; the other reverse primer (5′-CTG GCT CTT GTC
ATT TCC TG-3′) amplified the wild-type allele, which was
seen  as  a  384-bp  product.  Primer  sequences  and  PCR
conditions are available on request.
RESULTS
Clinical  findings:  Forty-three  individuals  with  panretinal
dystrophies  were  identified  in  the  population  of  48,000,
TABLE 1. PRIMER SEQUENCES FOR AMPLIFICATION OF MERTK.
Primer sequence (5′-3′) Exon Primer sequence (5′-3′) Exon
CCACTCGGCACTCACTG 1 GAAACACGTTTCTTCTAGGGG 11
AGTGGGTGGAGGGTGTTT   TGCTGCTTTTAAAGACATTTTG  
TGTGTGTGTTAATGAATTCTGCT 2 AAGGTTGCACCATTGCAC 12
GAACTCAGGAGGTGGAGG   GTGCCAGATCTGAGTTTCAA  
TGCGTACAATGGCCTAGC 3 TGGTTTGCGATGTGGG 13
TGCTGATAGATTTGCAAGGTT   CTTGGTGACCAGTGTTCCA  
GAGCAAGACTCCATCCCC 4 AGCCCTACTAGCCCCTGA 14
CCCATAACTTTGCTGCCA   CTGGGTGAAAACCTCAATGT  
TCTCCATAGCTAGCACACCTTT 5 TGTGAGTTAGGCGCTCTTG 15
TGAGTTGTCCAAGGTCACAA   CAACCCTGGACACACAGG  
GGGAGGCTCCTCTTGAAA 6 TTGCCAAGAAGTTTAAGGTTT 16
GCTGGACACTGAAGCAGG   AAGCCACACCATCCCC  
CCCAGAAAGGAAGCAGGT 7 CACAGGCTGGTGGTGTCT 17
CGCCTCAATAATTTTCTCCTC   TCTGAGCAAGCTGCCAAC  
TTGAAAAGGTGAAAATGTGCT 8 AGCAGTGCGTCTCACACA 18
TGAAAGGTGCCTTGCCTA   GTGTCTGTGGGTTCCACC  
ATGCTGTGGAAGTGTGGC 9 TTGTATAAATATTAGGCCACCAAA 19A
ACTCCTCCTGCTTTTGCC   CCCATTCAGGATGTACCG  
TCGCATGGTCTCAGCTTAC 10 CCACTGGACTTGAACATCG 19B
GGGTATGCATAAGGCAGG   TTCATCTGGTGCTTTGGG  
Molecular Vision 2011; 17:1485-1492 <http://www.molvis.org/molvis/v17/a167> © 2011 Molecular Vision
1486T
A
B
L
E
 
2
.
 
C
L
I
N
I
C
A
L
 
F
I
N
D
I
N
G
S
 
I
N
 
S
I
X
 
H
O
M
O
Z
Y
G
O
U
S
 
A
N
D
 
O
N
E
 
H
E
T
E
R
O
Z
Y
G
O
U
S
 
I
N
D
I
V
I
D
U
A
L
S
 
C
A
R
R
Y
I
N
G
 
T
H
E
 
F
A
R
O
E
S
E
 
M
E
R
K
 
F
O
U
N
D
E
R
 
M
U
T
A
T
I
O
N
.
I
D
A
g
e
 
o
f
o
n
s
e
t
A
g
e
 
a
t
 
f
i
r
s
t
/
l
a
s
t
 
e
x
a
m
V
i
s
u
a
l
a
c
u
i
t
y
 
a
t
f
i
r
s
t
 
e
x
a
m
V
i
s
u
a
l
a
c
u
i
t
y
 
a
t
l
a
s
t
 
e
x
a
m
R
e
f
r
a
c
t
i
o
n
r
i
g
h
t
R
e
f
r
a
c
t
i
o
n
 
l
e
f
t
F
u
l
l
-
f
i
e
l
d
 
E
R
G
(
f
f
E
R
G
)
P
e
r
i
m
e
t
r
y
 
(
a
g
e
)
D
a
r
k
 
a
d
a
p
t
a
t
i
o
n
1
8
6
9
1
6
/
3
2
6
/
1
2
6
/
1
2
1
/
6
0
1
/
6
0
+
2
.
5
0
–
1
.
5
0
x
1
0
°
+
2
.
5
0
–
0
.
5
0
x
1
7
0
°
F
l
a
t
T
V
 
2
–
3
°
 
(
3
2
)
N
o
 
r
o
d
 
a
c
t
i
v
i
t
y
2
3
2
8
9
/
3
5
6
/
7
.
5
6
/
9
6
/
6
0
0
.
5
/
6
0
−
4
.
5
0
–
3
.
0
0
x
0
°
−
4
.
5
0
–
3
.
0
0
x
0
°
F
l
a
t
P
a
r
a
c
e
n
t
r
a
l
 
i
s
l
a
n
d
s
 
(
3
5
)
N
o
 
r
o
d
 
a
c
t
i
v
i
t
y
1
1
3
6
2
4
/
3
2
6
/
3
6
6
/
2
4
H
M
0
.
5
/
2
4
E
m
m
e
t
r
o
p
i
a
E
m
m
e
t
r
o
p
i
a
N
.
d
.
T
V
 
1
–
2
°
N
.
d
.
1
0
6
5
6
/
3
0
6
/
6
6
/
9
1
/
6
9
1
/
6
0
+
0
.
5
0
0
.
0
0
–
1
.
2
5
x
1
6
0
°
S
u
b
n
o
r
m
a
l
T
V
 
3
–
5
°
N
.
d
.
1
0
2
1
0
2
4
/
2
7
2
/
6
0
3
/
6
0
1
/
6
0
1
/
6
0
E
m
m
e
t
r
o
p
i
a
E
m
m
e
t
r
o
p
i
a
N
.
d
.
T
V
 
5
°
 
p
l
u
s
 
p
e
r
i
p
h
e
r
a
l
 
i
s
l
a
n
d
s
N
.
d
.
2
4
9
*
8
6
/
3
5
6
/
6
6
/
6
6
/
1
2
6
/
1
8
−
6
.
0
0
–
0
.
5
0
x
9
0
°
−
6
.
5
0
R
e
d
u
c
e
d
‡
2
0
–
5
0
°
D
i
p
h
a
s
i
c
.
 
T
h
r
e
s
h
o
l
d
e
l
e
v
a
t
i
o
n
 
1
 
l
o
g
 
u
n
i
t
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A
b
b
r
e
v
i
a
t
i
o
n
s
 
N
.
d
.
:
 
n
o
t
 
d
o
n
e
,
 
H
M
:
 
h
a
n
d
 
m
o
v
e
m
e
n
t
s
,
 
T
V
:
 
t
u
n
n
e
l
 
v
i
s
i
o
n
,
 
*
:
 
h
e
t
e
r
o
z
y
g
o
u
s
.
Molecular Vision 2011; 17:1485-1492 <http://www.molvis.org/molvis/v17/a167> © 2011 Molecular Vision
1487corresponding to a prevalence of 1 in 1,100. Of these, 17 out
of 18 syndromic cases were diagnosed with Bardet–Biedl
syndrome. The remaining 25 cases of nonsyndromic RP were
either isolated cases or belonged to one of three families (882,
232, 801) with three or more affected family members. The
prevalence of nonsyndromic RP in the Faroe Islands is thus 1
in 1,900.
Twenty-one  individuals  with  nonsyndromic  RP
consented to participate in the study. Six of these belonged to
a family with a distinct phenotype in which a mutation in
protocadherin 21 (PCHD21) has been identified [15].
The clinical information that was available covered a time
span of 60 years and included many different examination
procedures (Table 2). No new examinations were performed.
The patients with MERTK mutations had a severe phenotype
with onset of night blindness in the first decade, a rapidly
progressive  deterioration  of  central  vision,  and  severely
affected visual fields during the second decade. Full-field
ERGs were mostly nondetectable at first examination, but in
the youngest individuals residual rod and cone responses were
still recordable. Dark adaptation showed some residual cone
activity but no signs of rod activity. Blindness was mostly
complete or near complete at the age of 40. Fundus pictures
(Figure 1) revealed a generalized, diffuse, retinal pigment
epithelial (RPE) atrophy with early mottling, followed by
more or less pronounced peripheral hyperpigmentation and
marked central atrophy. Narrow vessels and pale optic discs
appeared  relatively  late  but  with  large  interindividual
variation.
Genetic analyses: A genome-wide search for homozygosity
revealed a homozygous region on chromosome 2q that was
common to patients from four families (Figure 2A). The core
haplotype  was  6.1  Mb  (positions  111.6–117.7  Mb)  and
included  the  RP  gene  MERTK  (Appendix  1).  Sequence
analysis of exons 8–19 in MERTK in patient 186 was normal,
whereas exons 1–7 could not be amplified by PCR. Single
nucleotide  polymorphism  (SNP)  analysis  in  an  obligate
heterozygous carrier showed a deletion of an estimated 91 kb
encompassing  exons  1–7  (Figure  2B).  PCR  across  the
estimated  deletion  resulted  in  an  abnormal  PCR  product
harboring the deletion breakpoints. Subsequent sequencing
identified the exact breakpoint of the deletion, which can be
described  as  chr2  (HG18):112,364,622_
112,455,675del91,054 (Figure 2C). A targeted PCR assay was
Figure  1.  Fundus  aspects  from  two
patients  homozygous  for  a  MER
tyrosine  kinase  protooncogene
(MERTK)  deletion.  A-C:  22-year-old
female (patient 106); the central black
spot. The central black spot is an artifact
to reduce reflexes from the Zeiss fundus
camera. A: In the posterior part of the
retina,  near-normal  calibrated  central
arterioles  and  a  normal-appearing
optical nerve head are evident. B: In the
inferotemporal  aspect,  widespread
mottled pigment epithelial atrophy and
heavy  pigment  aggregates  partly
sheeting the retinal venules are seen. C:
In the macular region, distinct, nearly
circular, foveal atrophy is present. D: In
the left eye from a female age 35 years
(patient  232),  marked  atrophy  of  the
optic papilla, constricted arterioles, and
distinct  central  pigment  atrophy  are
present.
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1488developed allowing carrier screening for the deletion. This
analysis showed that the seven patients, from whom DNA was
available, were homozygous for the deletion, whereas seven
family members were carriers (Figure 2D).
Patient 249 from family 882 had a father unrelated to the
other family members. She was heterozygous for the deletion,
but sequencing of MERTK did not reveal another mutation,
indicating that RP could be caused by mutations in a different
gene in this patient.
Screening of 94 anonymous Faroese controls revealed
three heterozygous carriers, and thus the carrier frequency is
approximately 3%. Assuming Hardy–Weinberg equilibrium,
the  carrier  frequency  corresponds  to  an  incidence  of  RP
caused by MERTK mutations in the Faroe Islands of around 1
in 3,940. This is in concordance with the observed prevalence
of 11 affected patients in a population of 48,000, i.e., 1 in
4,360.
DISCUSSION
The high prevalence of nonsyndromic RP of 1 in 1,900 in the
Faroe Islands can partly be explained by a founder effect, with
a MERTK deletion being responsible for around 30% of RP
and a PCDH21 mutation responsible for around 25% [15].
Linkage data suggest that the remaining RP cases are caused
by mutations in several other genes (data not shown).
The  clinical  picture  of  the  patients  with  a  MERTK
deletion  reported  here  is  very  similar  to  descriptions  in
previous reports showing a severe rod–cone dystrophy with
early  onset  in  the  first  decade  (summarized  in  [13]).  In
addition  to  symptoms  seen  in  other  generalized  retinal
dystrophies,  the  fundi  of  patients  with  MERTK  mutations
develop an early bull’s eye central atrophy, which may guide
the  mutation  analysis.  In  contrast  to  early  onset  retinal
dystrophies  of  Leber  type  that  mostly  exhibit  high
hypermetropia, emmetropia or low myopia was present in
most Faroese MERTK patients.
The heterozygous patient 249 from family 882 (Figure
2A) with apparent pseudodominant inheritance of RP was 8
years old when examined the first time. She is now 54 years
old and nearly blind. Her fundi are typical for RP with narrow
arterioles, pale optic nerves, and peripheral spicule formation.
The diagnosis of RP is undoubtedly correct, but her symptoms
Figure 2. Pedigrees and analysis of the MER tyrosine kinase protooncogene (MERTK) deletion. A: Pedigrees of four Faroese families (882,
232, 233, 4002) with the MERTK deletion. B: Single nucleotide polymorphism (SNP) copy number analysis of a heterozygous carrier showing
that the deletion has a size of 91 kb. C: Sequence showing the breakpoints of the 91-kb deletion in a homozygous patient. D: The triple-primer
PCR assay generating a deletion-specific fragment of 264 bp and a wild-type fragment of 384 bp; lane 1, wild-type; lane 2, homozygous
patient; lane 3, heterozygous carrier; lane M, molecular marker.
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1489are  milder  than  in  the  homozygous  patients.  A  second
MERTK mutation was not identified, leaving the possibility
that her RP is caused by mutation(s) in a different gene.
In the RCS rat and mouse, which are naturally occurring
MERTK knockout models, retinal photoreceptor dystrophy is
a  consequence  of  a  defect  in  phagocytosis  of  shed  outer
segments by the retinal pigment epithelium. This results in
accumulation of outer segment debris in the subretinal space;
the retinal pigment epithelium and the photoreceptors lose
contact and the retina degenerates. Spectral domain optical
coherence tomography in humans with MERTK mutations has
shown thinning of the outer retinal layers and a debris-like
material in the sub-neurosensory space, which is similar to
findings  in  the  knockout  models  [12,13],  indicating  an
analogous disease mechanism in humans.
Subretinal Mertk gene transfer in young RCS rats has
shown  photoreceptor  survival  due  to  a  correction  of
phagocytotic activity by RPE cells, resulting in preservation
of retinal function [16-18]. Patients with Leber congenital
amaurosis  caused  by  RPE65  mutations  have  been  treated
successfully by gene replacement therapy [19-21]. RPE65
deficiency causes visual impairment due to depletion of visual
pigment from the phototransduction cascade, but the anatomic
features of the retina are well preserved. In addition, RPE65
is specific to the retinal pigment epithelium, and subretinal
injection  of  viral  shuttles  can  more  efficiently  transduce
retinal  pigment  epithelium  than  the  photoreceptor  cells,
possibly because of anatomic barriers. MERTK-related retinal
dystrophies share many features with those due to RPE65
mutations and could therefore be a good target for future viral-
mediated gene therapy in humans.
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1491Appendix 1.
Haplotypes of seven patients with retinitis pigmentosa of
the region on chromosome 2 surrounding MERTK. To access
the table, click or select the words “Appendix 1.” This will
initiate the download of a pdf archive that contains the table.
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